Novel Treatment for Diabetes - Focusing on GLP-1 and SGLT2

OR15-1

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy versus Placebo in Subjects with Type 2 Diabetes (SUSTAIN 1)
Christopher Sorli, Shin-ichi Harashima, George Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen and Stephen Bain

OR15-2

GLP-1 Receptors Exist in the Parietal Cortex, Hypothalamus, and Medulla of Human Brains and the GLP-1 Analog Liraglutide Administered in the Context of a Cross-over, Randomized, Placebo-Controlled Trial Alters Brain Activity in Response to Highly Desirable Food Cues in Individuals with Diabetes
Olivia M. Farr, Michail Sofopoulos, Michael A. Tsoukas, Fadime Dincer, Bindiya Thakkar, Ayse Sahin-Efe, Andreas Filippaios, Jennifer Bowers, Alexandra Srnka, Anna Gavrieli, Byung-Joon Ko, Chrysoula Liakou, Nickole Kanyuch, Sofia Tseleni-Balafouta and Christos S. Mantzoros

OR15-3

Robust Dose-Dependent Glucose Lowering and Body Weight (BW) Reductions with the Novel Oral Formulation of Semaglutide in Patients with Early Type 2 Diabetes (T2D)
Serge Jabbour, Thomas R Pieber, Julio Rosenstock, Marie-Louise Hartoft-Nielsen, Oluf Kristian Højbjerg Hansen and Melanie Davies

OR15-4

Consistent HbA1c Changes with Empagliflozin/Linagliptin Irrespective of Body Mass Index, Renal Function, or Gender
Kamlesh Khunti, Sanjay Patel, Egon Pfarr, Angelo Del Parigi and Christopher Lee

OR15-5

The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial Glucose in a Multiple-Dose Clinical Trial
Eric G. Vajda, Douglas K. Logan, Kenneth Lasseter, Danielle Armas, Diane J. Plotkin, J. D. Pipkin, Yong-Xi Li, Rong Zhou, David J Klein, Xiaoxiong Wei, Stacy Dilzer, Lin Zhi and Keith B. Marschke

OR15-6

Dapagliflozin Induces Ketosis in Patients with Type 1 Diabetes
Husam Ghanim, Nitesh D Kuhadiya, Salman Khan, Manisha Garg, Kelly Green, Sanaa Abuaysheh and Paresh Dandona